268 related articles for article (PubMed ID: 25733806)
21. Blood-brain barrier permeability study of ginger constituents.
Simon A; Darcsi A; Kéry Á; Riethmüller E
J Pharm Biomed Anal; 2020 Jan; 177():112820. PubMed ID: 31476432
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
23. Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism.
Kim HJ; Kim IS; Rehman SU; Ha SK; Nakamura K; Yoo HH
Bioorg Med Chem Lett; 2017 Apr; 27(8):1826-1830. PubMed ID: 28274629
[TBL] [Abstract][Full Text] [Related]
24. Predicting drug pharmacokinetics in humans from in vitro metabolism studies.
McGinnity DF; Riley RJ
Biochem Soc Trans; 2001 May; 29(Pt 2):135-9. PubMed ID: 11356141
[TBL] [Abstract][Full Text] [Related]
25. Promotion of Mitochondrial Biogenesis via Activation of AMPK-PGC1ɑ Signaling Pathway by Ginger (Zingiber officinale Roscoe) Extract, and Its Major Active Component 6-Gingerol.
Deng X; Zhang S; Wu J; Sun X; Shen Z; Dong J; Huang J
J Food Sci; 2019 Aug; 84(8):2101-2111. PubMed ID: 31369153
[TBL] [Abstract][Full Text] [Related]
26. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.
Ma JD; Nafziger AN; Villano SA; Gaedigk A; Bertino JS
Antimicrob Agents Chemother; 2006 Apr; 50(4):1130-5. PubMed ID: 16569820
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory Effects of Eight Green Tea Catechins on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activities.
Satoh T; Fujisawa H; Nakamura A; Takahashi N; Watanabe K
J Pharm Pharm Sci; 2016; 19(2):188-97. PubMed ID: 27518169
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.
Linnet K; Olesen OV
Drug Metab Dispos; 1997 Dec; 25(12):1379-82. PubMed ID: 9394027
[TBL] [Abstract][Full Text] [Related]
29. Protein-Ligand Identification and
Lim SYM; Loo JSE; Alshagga M; Alshawsh MA; Ong CE; Pan Y
Int J Toxicol; 2022; 41(5):355-366. PubMed ID: 35658727
[TBL] [Abstract][Full Text] [Related]
30. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.
McGinnity DF; Griffin SJ; Moody GC; Voice M; Hanlon S; Friedberg T; Riley RJ
Drug Metab Dispos; 1999 Sep; 27(9):1017-23. PubMed ID: 10460801
[TBL] [Abstract][Full Text] [Related]
31. In vitro Inhibitory Effects of Cynaroside on Human Liver Cytochrome P450 Enzymes.
Wang L; Ma X; Wang J; Li C
Pharmacology; 2019; 104(5-6):296-302. PubMed ID: 31587003
[TBL] [Abstract][Full Text] [Related]
32. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
33. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
34. Binding and Metabolism of Brominated Flame Retardant β-1,2-Dibromo-4-(1,2-dibromoethyl)cyclohexane in Human Microsomal P450 Enzymes: Insights from Computational Studies.
Ma G; Yu H; Han C; Jia Y; Wei X; Wang Z
Chem Res Toxicol; 2020 Jun; 33(6):1487-1496. PubMed ID: 32243142
[TBL] [Abstract][Full Text] [Related]
35. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
36. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of carteolol by cDNA-expressed human cytochrome P450.
Kudo S; Uchida M; Odomi M
Eur J Clin Pharmacol; 1997; 52(6):479-85. PubMed ID: 9342584
[TBL] [Abstract][Full Text] [Related]
38. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
39. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone.
Gong EC; Chea S; Balupuri A; Kang NS; Chin YW; Choi YH
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498658
[TBL] [Abstract][Full Text] [Related]
40. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.
Wang ZX; Sun J; Howell CE; Zhou QY; He ZX; Yang T; Chew H; Duan W; Zhou ZW; Kanwar JR; Zhou SF
Fundam Clin Pharmacol; 2014 Oct; 28(5):551-82. PubMed ID: 24612223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
